This article was originally published on July 20, 2022, and is being promoted by Stansberry again without any changes to the original “presentation,” so we’re re-posting our article here to answer some of those questions. I’ve added a brief follow-up on the performance of those stocks at the bottom of the article.
The lead-in to Dr. David Eifrig’s latest teaser pitch lays it on a bit thick:
“‘This WILL BE the Biggest Shock to Retirement in More than 40 Years’
“No one’s paying attention, but this development will have a far bigger impact than recession… inflation… or who controls Congress or the White House.
“Here’s exactly what’s happening… how it could lead to 1,000% gains for folks who act now… and why, if you’re over 40, the stakes could literally be life or death.”
Eifrig has long been one of the more sober newsletter editors over at Stansberry, Gumshoe readers have often told me that they like his entry-level newsletter Retirement Millionaire, which generally recommends pretty safe and stable companies and throws in Eifrig’s commentary and suggestions on health and medicine… though that’s often true, it’s the relatively inexpensive “entry level” newsletters that are generally the most popular, whether that’s just because they don’t try too hard to pick odd investments or just because expectations are lower because they tend to cost only $50 or $100 a year (the options advisories and other more esoteric or active trading services that cost a few thousand dollars a year might wisely be met with more scrutiny).
And now he’s launching a new service as the market is in a bit of a tailspin — this new one is called Prosperity Investor, and it’s focused specifically on investing in the broad health care sector… something that Eifrig has pretty much always included as a heavy weighting in his other newsletters, given his medical background. The “Charter Member” deal they’re offering is $2,000 for two years, with no refunds (though, to be fair, also no auto-renew tied onto the order), and I guess the Stansberry folks will decide by then whether this is going to be an ongoing publication — they think it’s worth $5,000 a year, but they won’t really know until they see if people sign up and like it.
The promise? Here’s what Eifrig says he’ll do in this newsletter:
“… what I’m about to show you is actually a big part of the answer to what’s going on – and how you’re probably feeling – today.
“It’s something that could both show you astonishing, quadruple-digit profit potential…
“And help you to recover, protect, and compound your wealth with the most low-risk wealth compounders in the markets.
“Because almost none of this is speculation.
“What it does involve is a massive story that almost no one understands…
“Unfolding in the biggest, most important, and most bulletproof sector of our economy.
“There’s no better place to find ‘forever stocks’ – the kind you can and should stash away for as long as you can with barely a second thought, no matter what the market or economy is doing.
“And today, I’ll show you a big, immediate solution to the pain so many of us are feeling in the markets.”
So that place to find “Forever” stocks is, of course, the healthcare sector, and he tells us why he likes it so much…
“This sector also famously outpaces inflation year after year – something you can use to your tremendous advantage if you know how.
“Meaning today, you could see the biggest gains of a lifetime in some of the most defensive stocks on the planet…
“In some ways, it makes perfect sense you’d find these gains in health care.
“You were likely greeted into this world by a nurse or midwife.
“And you’ll likely have a health worker by your side when you leave it. We’re health care consumers the whole time.
Are you getting our free Daily Update
"reveal" emails? If not,
just click here...“By 2030, every Baby Boomer – and 20% of all Americans – will be retirement age. And the same trend is playing out all over the world.
“This aging population is using more care. And our growing lifespans mean we’re using it for longer.
“The tailwinds are obvious….
“Health care makes up nearly 20% of the U.S. economy.
“It employs over 20 million people.
“At $4.1 trillion, it’s not just bigger than every penny spent nationwide on food… cars… or energy.
“It’s bigger than all three put together….
“In this context, an innovation that can reduce costs or expand profits by even 1% can be worth billions.
“A treatment that can improve outcomes by 5% can become the best-selling drug in the world.
“Something you may have never considered when it comes to investing.”
And he spends some time talking up the innovation in healthcare, from personalized cures to technology breakthroughs that let us use the vast amounts of data we’ve collected about health and human biology, that is bringing a “singularity” of sorts for this sector of the market… in his words…
“I’ll show you today why we’re within years or possibly months of an event I call the ‘Health Care Singularity.’
“A moment when data and artificial intelligence empower treatments and cures unlike anything we’ve ever seen – and they’re available to us almost instantly.
“This change could be bigger than electric cars… new forms of energy… or 21st century space exploration.
“I suspect it could give rise to a company bigger and more important than Amazon…
“And deliver the same kind of gains for early shareholders.”
And a little tidbit I didn’t know…
“A study of 49 industry groups – dating back to 1926 – found that health care stocks are the single best hedge against inflation anywhere in the markets.
“Twice as good as gold.
“Nothing else came anywhere close.
“That’s because demand for health care doesn’t change much, no matter the economic environment… and providers have almost unlimited pricing power.”
The ad “presentation” is a long one, so I’ll spare you more quotes and details — suffice to say, he thinks healthcare will remain the largest part of the US economy, he sees huge opportunity as technology advances, and he sees big pharma stocks having enough cash on hand to buy out most of the little biotech ideas that are percolating out there… and yet, the weak market and some ups and downs from COVID have led to the sector being attractively valued.
So now we get to the part I’m interested in… what are the stocks he says you should buy and hold, essentially forever, to earn 20%+ annual returns? The real teaser bait in the ad is for two special reports, one called “7 “Forever” Health Stocks to Potentially Double the Market, Every Year” and a second one called “The No. 1 Opportunity of My Life: 3 Chances at 1,000%-Plus Gains in the Health Care Singularity.”
We’ll start with the “7 “Forever” Health Stocks to Potentially Double the Market, Every Year”… what can the Thinkolator find?
He doesn’t drop many specific hints, but he does show us a few stock charts proving that these “mystery stocks” did well during the last market crash, in 2008… so that should help us get some answers.
Going by an exact match to the two charts shown, then, Mystery Stock #1 is Gilead (GILD), which posted an 11% return in 2008 while the S&P dropped about 37%.
Mystery Stock #2 is Omega Healthcare Investors (OHI), which is also very likely the “almost a 10% yield” stock he hints at (the clue being, “Another one pays a nearly 10% dividend yield today.”)
Some stocks that I suspect are in that “Mystery Stock” portfolio did not do as well back in 2008, of course — UnitedHealth (UNH) would be a logical Eifrig pick in the health insurance sector, that or Humana (HUM), and both of those did worse than the broad market in 2008, they lost roughly half their value… and Pfizer (PFE), another likely pick and one he mentions favorably, did a little better than the market, but still lost money (down 22%, about the same as Eli Lilly (LLY)). Medtronic (MDT) has often been a favorite in the Stansberry stable and might also fit into this seven-stock portfolio, but it had a very average year in 2008, down by about 37%, just like the S&P 500. Even Johnson & Johnson (JNJ) and Novartis (NVS) fell a little bit that year, roughly 10%. One of the few other big pharma and healthcare stocks to eke out a gain that year was AstraZeneca (AZN), though the chart doesn’t quite match Eifrig’s. Even mighty Roche (RHHBY) lost 10% in 2008.
So can we name more than those two stocks out of the seven? Here’s one more clue…
“I asked the No. 1 ranked health care analyst in America about one of these stocks… and this is what he said:
‘It’s God-like. The people that run this company have eyes on the health care of one in every three Americans. If this was the only stock you owned for the last 20 years – you won. A 20-bagger in that time. And I see NO reason why it’s not another 10-bagger over the next decade. When this stock falls because of macro concerns – you buy it. End of story.'”
That’s almost certainly UnitedHealth (UNH), which is now the largest company in the healthcare sector (it jumped above Johnson & Johnson (JNJ) not long ago) — that company does indeed insure or touch the insurance coverage of one in three Americans. The only other healthcare company that might boast that breadth of connection is probably CVS Health (CVS), which also sells drugs and other stuff to about one in three US residents… but it hasn’t had anywhere near a 20X return over the past twenty years, and UNH is a hair above that, with shares up 2,300% in two decades (or 2,700% if you count dividend reinvestment). CVS has beaten the S&P 500 during that time, but still only returned 642% (vs. 546% for the S&P 500).
And we get one more “chart” clue as well, “The Nasdaq has fallen 33% since November. One of these “forever” stocks is up as much as 25% over the exact same period.”
Which is also, sadly, a perfect match for UnitedHealth — so we don’t get a fourth easy match in there. That’s three matches for Eifrig’s “7 ‘Forever’ Health Stocks to Potentially Double the Market, Every Year.”
What might the four others be? I’ll throw out some possibilities — I wouldn’t be surprised if Eifrig is also picking Pfizer (PFE), among the lowest valuations among mega-pharma, and cancer drug leader Bristol-Myers Squibb (BMY), as other big-pharma picks. And elsewhere in healthcare we might see him picking CVS Health (CVS), a leader in both pharmacy services and health insurance with a pretty-much-unrivaled US footprint (apologies to Walgreen/Boots Alliance (WBA)). I suspect that the two big lab equipment/services providers for the healthcare segment, Thermo Fisher (TMO) and Danaher (DHR) are probably both a little too richly valued for Eifrig to put them into a “forever” portfolio at this point, but maybe PerkinElmer (PKI) or Becton, Dickinson (BDX) would make the cut. Also probably too expensive are the somewhat more niche and growth-focused technology leaders Intuitive Surgical (ISRG) and Illumina (ILMN), for exposure to robotic surgery and DNA sequencing equipment, but perhaps one of them is in there. (For what it’s worth, Eifrig pitched both TMO and CVS about a year ago in his Retirement Trader ads — those two picks have beaten both the market and the broader healthcare sector, though the other three stocks he teased at the time are down 70-80%, like a lot of other more speculative and growth-y stuff).
There’s probably a medical devices company in there as well, If you’re going with “Forever” I’d guess that he’s picking Medtronic (MDT), which is also trying to be the future competitor for ISRG, but it could also be Boston Scientific (BSX). I kind of doubt that Eifrig is including more than one REIT in that basket, that would be a pretty big “overweight,” but he could reasonably pick Ventas (VTR) as well, for senior living facilities as well as some exposure to lab complexes and medical office buildings — or, if more aggressive, the real biotech lab-focused REIT, Alexandria Real Estate Equities (ARE). Throw on some orthepedic surgery exposure with Zimmer Biomet (ZBH) or Stryker (SYK), perhpaps? Both of those look fairly expensive, but in part that’s because of the many knee and hip replacements that were delayed by COVID. Or perhaps Eifrig is including a distributor, like Mckesson (MCK) or Cardinal Health (CAH), or, if he’s being a little sneaky, a pharma royalty company like Royalty Pharma (RPRX) or the smaller Ligand (LGND) (OK, the latter is likely far too risky — they’re hugely reliant on Kyprolis royalties from Amgen (AMGN)).
Lots of options, for sure… so, best guess? I’m sure about Omega Healthcare Investors (OHI), Gilead (GILD) and UnitedHealth (UNH), and for the other four I’d throw Pfizer (PFE), Medtronic (MDT), Bristol-Myers Squibb (BMY), and CVS Health (CVS). Round it out to ten and I might add Ventas (VTR), PerkinElmer (PKI) and Cardinal Health (CAH). I’d bet at least five or six of his seven picks are in that group of ten, but it would be a small bet.
I don’t spend a lot of time analyzing big pharma companies or healthcare in general, I tend to leave my investing in that sector to the professionals (I have money in both Vanguard Health Care (VGHCX) and Primecap Odyssey Growth (POGRX), otherwise I tend to be most tempted by the real estate and medical equipment companies — I own both Intuitive Surgical (ISRG) and Illumina (ILMN) in that group), but for the most part all those stocks I named have justifiable valuations and potentially steady business growth — there’s always some churn in pharma as big drugs grow into blockbusters and then fall as their patents expire, but there’s also more stability in insurance and medical devices and distribution or pharmacy benefit management, along with the couple real estate names tossed in there.
Want to buy a bunch of those and hold for ten or twenty years? Many of them are more reasonably valued than they’ve been in a while, and certainly demand for healthcare is only growing in the US, which is by far the most lucrative market for pharmaceuticals, as the population ages.
Perhaps there will be a genuine reckoning at some point, with real price controls for drugs or other meaningful changes to the regulatory regime to try to manage the fact that the US continues to spend so much more on healthcare than the rest of the world, with often worse results… but I wouldn’t count on Congress getting its act together to try to eat into Big Pharma’s profits anytime soon, particularly not after a pandemic that still has everyone on edge and has reinforced the need for medical research and innovation. The US healthcare system might not be great at making most of us healthier most of the time, but that’s probably partly lifestyle driven … and our healthcare system is great at, and often wildly incentivizes, treatments that prolong life or provide genuine cures or help to manage or slow deadly diseases like cancer. The companies in the business surely know this, and they’re mostly doing A-OK and continuing to push the innovation.
And we get one more tease for Eifrig’s letter, this is the second bit of bait: What are the stocks teased in the special report, “The No. 1 Opportunity of My Life: 3 Chances at 1,000%-Plus Gains in the Health Care Singularity”? … more from the ad:
“Step Two: Position Yourself for 10x Upside Potential in the Health Care Singularity
“The ‘forever’ stocks I just told you should be the foundation of wealth that I expect you’re never likely to outlive… or have to worry about in any market.
“But the biggest winners – by far – will be the innovators.
“Like medical robotics firm Intuitive Surgical (ISRG), up more than 10,000% all time:
“Or biotech pioneer Regeneron, up more than 9,000% since 2005:
“I’m 100% certain that the setups today could be similar – or better.
“I strongly suspect the next Amazon-like company is in its early stages.”
So which of these riskier stocks does Eifrig like? More from the pitch:
“One of these companies created a simple, at-home test for an extremely deadly and common type of cancer.
“It affects more people than all other cancers combined.
“This technology is cheaper than existing detection methods and non-invasive. It can save millions of lives from early detection… and billions of dollars in in-person medical costs.
“It’s already approved by the FDA… covered by Medicare… and has some of the largest insurers in the largest states.
“The stock is so cheap today that it could rise 15-fold just to get back to where it was before the recent market freak-out. That’s a once-in-a-lifetime buying opportunity.”
Thinkolator sez that one is almost certainly DermTech (DMTK). They did hit about $80 during the mania of early 2021, and were recently down below $5, so that would be a 15X return to get back to their all-time highs. They sell an at-home melanoma test, you basically use a special “Smart Sticker” to peel off some skin cells from your mole and send it in to DermTech’s lab for analysis. They have been getting a growing number of insurance providers on board, and do have Medicare approval for at least part of their test (they do two tests on the sample, one of them is covered by Medicare). Revenue has been growing pretty nicely, so I guess they’re getting some uptake, though the risk is that their costs are growing a lot faster than their revenue and they’re losing quite a bit of money still, so they really need to grow to a much larger scale to make this business make sense — melanoma is a big deal, and there have been other attempts at improving the diagnosis without biopsy in the past… I don’t know what their odds are of breaking through, but it is at least a huge market.
“Another is harnessing the power of medical AI, which I’ve told you so much about today.
“It’s handheld device plugs into any doctor’s smartphone, replacing machines that cost 10 times as much – without the AI!
“And making this screening available at the point of care – in doctor’s offices and even in the field, where before patients had to spend critical hours waiting for a specialist at the hospital.
“The founder is a trailblazer with three hugely successful companies already under his belt. He won a presidential award for his contributions to genome mapping. This latest venture is backed by Bill Gates, among others.
“Revenue was up 35% last year… and this AI-driven health company is just getting started.”
That’s almost certainly Butterfly Network (BFLY), which we’ve written about before — that was pitched by Alexander Green for its handheld ultrasound device back in April, and I went into quite a bit of detail back then, so I’ll just refer you to that article for more of my thoughts (short answer? Great story, but they’ve fallen far short of their growth goals and there seems to me to be a lot of competition).
One more?
“The last company is a pure biotech play – with a chance at the astronomical gains you can see when a groundbreaking drug wins approval.
“Its technology was all the buzz at the latest American Society of Clinical Oncology meeting – the most prestigious cancer conference in the world.
“And they just penned a more than $4 billion partnership with pharma giant Bristol Myers Squibb.
“Believe me, Bristol doesn’t throw around that kind of money when it doesn’t consider the potential to be nearly a sure thing.
“Folks, these are the kinds of investments where even a single “win” can be incredible. I see the potential for 500%… 700%… even 1,000% gains if things go right – in every one of them.”
Best match here, sez the Thinkolator, is Immatics (IMTX), one of the biotechs that went public through a SPAC deal right as COVID was hitting in the Spring of 2020. They had a R&D deal with Celgene a few years ago, so that was acquired by BMY when they bought that biotech leader in 2019, and BMY recently “tripled down” on the deal by adding more programs and more potential funding. They haven’t ponied up anywhere near the full amount yet, but they have agreed to a total of about $4.2 billion if all the programs they have in mind reach milestone payments, so that matches the clues well. Probably those programs won’t all make it and Immatics won’t get the full $4.2 billion, but that’s still a lot of partnership muscle for a very small company (IMTX has a market cap of about $600 million), and, along with their own SPAC cash, it gives them quite a bit of time to see if their technology works. And if they come up with a big winner for BMY, eventually, there would be royalties to IMTX on top of that (none of the treatments they’ve partnered on are even out of Phase 1 clinical trials at this point, and most have never been tested on a human being, so we shouldn’t get ahead of ourselves).
What do they do? Mostly try to boost the T cell response to fight cancer cells… which is about as much as I can say before I start to sound as uninformed as I truly am. Here’s how they put it on their website:
“Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.”
Their pipeline is very early stage, just a couple drugs in phase 1 clinical trials and a bunch of preclinical R&D… so they’re not going to have a product approved anytime soon or generate royalties, but if they continue to make progress they could get some fat milestone payments from BMY or other partners along the way. Their spending so far has not been particularly high, as you would generally expect for a company that’s not running big clinical trials yet, so the nearly $300 million they have in cash right now should be enough to keep things going for at least a couple years.
Whether the treatments they’re developing end up being effective or not, I can’t hazard a guess, but the company looks pretty well-positioned on the financing side. If you like speculating on early stage biotech, with all the risks that entails, then a cancer immunotherapy company with plenty of cash and a big BMY partnership is probably a decent place to start… just be ready to be patient, and know up front that the risk of failure is high.
And yes, even big deals with big companies can fail. Bristol-Myers, like most big pharma companies, does throw their money around in big chunks — sometimes it works, sometimes it doesn’t, very little is really 100% predictable in biology. They just ended their expensive partnership with Nektar Therapeutics (NKTR) after some trial failures, for example, despite spending a couple billion dollars.
But I guess you know that — touted potential of 1,000% gains pretty always comes with a meaningful risk of 100% losses.
So… interested in betting on Dr. David Eifrig’s “Healthcare Singularity” ideas? Think that his “forever” healthcare stocks look appealing for some long-term compounding, or that his three riskier biotech speculations have some appeal? I’m sure that many of you have more insight into the science than I do, so feel free to opine on any big stuff I missed… or otherwise let us know whether you’d think about buying any of the dozen or so companies we’ve mentioned here. Thanks for reading!
P.S. Here’s the chart for how those six stocks that I’m quite sure of (out of the ten total), have done so far since the ad started running in mid July… that’s the S&P 500 in orange, down about 4%, so there have been a couple of stinkers among the more speculative stocks pitched, but in general the big health care stocks have done well so far.
Disclosure: Of the companies mentioned above I own shares of Intuitive Surgical and Royalty Pharma, and have money invested with both the Vanguard Health Care and Primecap Odyssey Growth mutual funds. I will not trade in any covered stock for at least three days after publication, per Stock Gumshoe’s trading rules.
Very good analysis.he mentioned centene as one of the stocks also
Thanks, I don’t think I’ve ever looked at that one before (If anyone else is curious, Centene (CNC) runs mostly government-connected healthcare plans, like Medicaid, Medicare and the Obamacare exchange plans — big company, roughly $50 billion market cap and trades at 16X forward earnings… not as steady as UNH, partly because it’s 1/10th as big, but probably cheaper).
David, is incorrect. Centene is not one of the stocks picked!
As always, a most excellent analysis, Travis.
Interestingly enough, I sold my DHR holdings just this morning. I’d made a nice profit, and found a few semiconductor stocks that seemed more interesting.
I still hold TMO and DMTK…at this point, I may hold TMO forever, since the cap gains are daunting!
TMO is indeed a phenomenal company, and has been a hugely successful investment for pretty much anyone who touched it — congrats! If I had to pick one stock as being like an ETF play on “biotech is getting more important,” it would be TMO. Sure ain’t cheap… but it hasn’t been cheap for a long, long time.
Danaher I owned years ago, before the 2008 crash… still really regret selling that one way too early, though it’s a wildly different company today than it was then.
check out stock screener at Tradingview, there´s a whole list of Health Technology stocks which rose abt20% starting july 19th when Doc aired and subscribers started buying
Looks like his pitch may have had an impact on the small caps in that group, though it’s hard to pinpoint causes in these volatile markets. The three small ones he teased were all up pretty nicely yesterday and today… though biotech as a whole was up, too, so it wasn’t just Eifrig. His pitch didn’t have an impact on any of the larger companies he touted as “forever” stocks, but that’s as you’d expect — even a very successful newsletter launch isn’t likely to impact the share prices of liquid multibillion-dollar companies.
Thanks for the insight!
Eifrig is a big wheel in the Stansberry organization. Stansberry is a very well oiled machine in the financial newsletter industry. They are part of Agora. They have lots of great research however the barrage of teasers is almost intolerable. Each newsletter pitches the other newsletters. There are some very capable members of the organization however never forget that they have ONE mission-sell, sell, sell.
Are the Newsletter publishers going broke because for the last three weeks on a daily basis there is another teaser for a $4000 to $5000 new subscription webinar pitching a better system. Eventually one could become newsletter broke. I guess greed is everywhere now days. What is best, losing $100000 in the stock market or wasting $100000 on misinformation newsletters. Eventually the well goes dry. This is my opinion for what it’s worth, consult with Travis of STOCK GUMSHOE before buying any expensive newsletter because there are no cash refunds only credits for other useless newsletters under the same umbrella. Hopefully we will run out of newsletters and their boring sale pitches will terminate at least for awhile I hope. Maybe I should turn on my spam email.
During periods of market turmoil like this, marketers have a hard time figuring out what will work… and they test and try a lot of different pitches. From 2009-2011 it was all, “the worst isn’t over, the world is going to end, there will be blood in the streets, and only my strategy can save you” — definitely a few folks have already rolled back to
That message, but subscribers are almost certainly down pretty much everywhere so the publishers are pushing hard to find something that works.
For what it’s worth… I noticed that Cathie Wood has been buying a lot of BFLY since early July 2022
I found BFLY very interesting a while back. Talked to the wife an LPN (nurse for 40 year) and she advised that “NOT EVERYONE” should be reading the ultrasound, since most can’t do it correctly. Just my 2 cents.
When I say “NOT EVERYONE” I am refering to the nurses and doctors at the clinic or hospital, who don’t have enough experience reading the ultrasounds. Also the “nurses” are NOT nurses they are MA or CNA who don’t have enough training as an LPN or RN has.
I agree. Had an ultasound 23 months ago and just got the results a few days ago, it took that long to decide to even look at it and then inform me that I had a heart abnormalty Great Canadian Health care system
Travis, you covered the seven and the three with the exception of BMY. He had some other speculative picks as well, for a total of 18
Thanks! Which of his picks do you find most appealing?
I warned Eifrig and readers here against his MELA pick years ago, and I wrote him yesterday regarding DMTK. Few of my colleagues outside of those with financial conflicts consider the melanoma test as worthy of more than rare, occasional use, as the test yields distressingly frequent equivocal results, and skin biopsies when performed properly, are neither particularly painful, nor disfiguring. So you have an expensive test that frequently results in biopsy anyway, and a resultant delay in definitive diagnosis. Add that they have been detailing me for about 5 years at least, has the adoption rate for the test been dramatic? Then the fact that one must take time discussing these points with patients, yet there is an incentive to do a biopsy. I neither engage in, nor condone unnecessary biopsies, I’m merely pointing to facts. I repeat my advice I wrote years ago for MELA: Invest in this one if you think you are nimble enough to trade it, as I don’t think it will be a long term winner. One dermatologist’s (and Mohs surgeon’s) point of view.
I do remember a bunch of penny stock letters pitching MELA many years back, didn’t know (or remember, at least) that Eifrig was also on board.
So, this sticker/genetic test of the skin cells has the same “probably need a biopsy anyway” downside as the MELA scanner? That’s too bad. Do you see a real at-home test for melanoma ever coming along?
I did comment on your site about MELA; I don’t know if your archives go back that far. As for an “at home” test, I doubt it, but who knows? So many of my patients would be wasting resources on (benign) seborrheic keratoses, and I have found melanomas between toes/perianal area/etc., so I don’t think you’re seeing the demise of the role of dermatologists in skin cancer detection any time soon, not to mention the fact that there are other skin cancers – even beyond the common basal cell and squamous cell carcinomas (e.g., Merkel Cell, sebaceous carcinoma, pleomorphic dermal sarcoma, cutaneous T-cell lymphomas, B-cell lymphomas, DFSP, extramammary Paget’s, etc.).
I am more interested in imaging techniques that will likely become in office adjuncts for diagnosis and delineation of margins of skin cancers such as two- and multi- photon microscopy, and confocal microscopy. The latter is the closest to being routinely seen in the clinical setting, but still some years away.
Disclaimer: The opinions stated here are my own, and should in no way be construed as representing those of my employer, nor ANY professional organization of which I am a member. I could be absolutely wrong on DMTK. I am neither a buyer, nor a short-seller of this stock. Best wishes, and prosperity to all in stockgumshoeland!
Thanks — I do remember your prior comments on MELA, really appreciate the input.
Hi Travis. My first time ever commenting. Former Irregular who foolishly left just under a year ago but continued reading your messages faithfully. Your reviews are simply amazing! THIS ONE did it for me and I just rejoined as an IRREGULAR. To think of the $ I’ve spent over the years for “learning lessons” is crazy. Fortunately, all of them have been under $100 and, truthfully, they were mostly garbage while trying to upsell you for the supposedly really valuable information. Sadly, friends of mine with more $ to play with have wasted thousands with little, and often poor results. I’ve told them all about you and your site! So, I’m truly excited to be back as an IRREGULAR and as my $ situation improves will no doubt opt for the Lifetime Membership Option. THANK YOU for your outstanding work on behalf of all of us who are just trying to get HONEST information to base our decisions on!
Thanks… and welcome back!
Great article, with just the kind of veracity and depth that I was looking for.
question for SKIN on this thread – have you had any experience with CSTL-Castle Biosciences- for melanoma biopsies, My dermatologist was less enthused re DMTK, but very constructive on CSTL. Doctors like to get paid, which is an issue for DMTK vs doing a biopsy (the Dr gets to bill for the biopsy but not the DMTK test). The potential for DMTK could lie not with traditional dermatologists, but rather for general practitioners in a value based care setting s or a tele health setting, where a weird looking mole could be tested with a DMTK patch as a first pass. The DMTK value proposition (their sales pitch) is a high percentage of biopsies are benign (wasted expense). Of course, the DMTK solution ain’t exactly cheap either.
I bought BFLY after decoding the Alex Green video and was up more than 100% a few weeks ago and they think it will continue to blowup. Healthcare is historically the best produing segment of the market so I am sure one or more of these stocks will go up. You are best to stay with money making companies instead of hoping for a drug approval as drug companies usually run in the red until they get approval. Good hunting.
does anyone know the weight loss blockbuster drug Prosperity Investor is pitching today. June 8. 2023